Literature DB >> 23688819

Tuberculosis screening and treatment compliance in human immunodeficiency virus patients.

F Viveiros1, M Mota, P Brinca, A Carvalho, R Duarte.   

Abstract

This study aims to evaluate compliance of HIV patients to TB screening and treatment, identifying determinants for non-compliance. We reviewed clinical records of all HIV infected patients first attended in a Portuguese-Infectious-Unit from 2007-2010 (152 patients). Screening included: symptom inquiry, chest x-ray, TST/IGRA. In 2008 a protocol was established with a TB outpatient clinic allowing patients to choose where to perform screening (decentralization). All patients were offered screening, 69 (45.4%) accepted. Before decentralization, out of 78 patients, 20 (25%) accepted screening. After decentralization, out of 64 patients, 49 (76.6%) accepted screening. Decentralization was associated with higher levels of acceptance (p<0.001), having an AIDS-defining-disease (p=0.002) and being older (p=0.04) was associated with lower screening acceptance. LTBI was diagnosed in 14 and active-TB in 18 cases; 14 cases of active-TB were later diagnosed during hospital appointments. For active-TB, being on HAART was related with treatment adherence (p=0.03). In this population, improving health care access was important for screening compliance.
Copyright © 2012 Sociedade Portuguesa de Pneumologia. Published by Elsevier España. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23688819     DOI: 10.1016/j.rppneu.2013.03.001

Source DB:  PubMed          Journal:  Rev Port Pneumol        ISSN: 0873-2159


  1 in total

1.  Risk Stratification and Factors Associated with Abandonment of Tuberculosis Treatment in a Secondary Referral Unit.

Authors:  Wanessa da Silva Peres Bezerra; Everton Ferreira Lemos; Thiago Nascimento do Prado; Larissa Taemy Kayano; Stefany Zacarin de Souza; Cláudia Elizabeth Volpe Chaves; Anamaria Mello Miranda Paniago; Albert Schiaveto de Souza; Sandra Maria do Valle Leone de Oliveira
Journal:  Patient Prefer Adherence       Date:  2020-12-03       Impact factor: 2.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.